Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.27 CAD | -0.49% | +37.71% | +81.51% |
Apr. 19 | Canopy Growth Slides After Constellation Directors Leave, Share Conversion | DJ |
Apr. 18 | Stocks to Watch : Canopy Growth, Metropolitan Bank, Netflix | DJ |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- With an enterprise value anticipated at 4.17 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Most analysts recommend that the stock should be sold or reduced.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+81.51% | 661M | C- | ||
+38.08% | 6.05B | B- | ||
-16.43% | 4.45B | C+ | ||
-12.46% | 3.06B | B- | ||
-0.21% | 3.04B | C | ||
-0.59% | 2.58B | - | D+ | |
+34.54% | 1.79B | - | ||
+0.93% | 1.66B | - | - | |
-10.63% | 1.63B | - | - | |
-12.50% | 1.54B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- WEED Stock
- Ratings Canopy Growth Corporation